Texas Mesothelioma Information | Surviving Mesothelioma

Mesothelioma in Texas

Texas Mesothelioma Fact Sheet

While mesothelioma is a problem in all states, the specific incident rate for Texas is 0.9 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in TX, recent TX mesothelioma-related court cases, mesothelioma specialists in TX and potential asbestos hotspots in Texas.

Texas Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Texas

Texas Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Texas Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Texas Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract: DESCRIPTION (provided by applicant): Malignant mesothelioma is an example of a solid tumor extremely unresponsive to conventional therapy, with few patients surviving for more than 12 months regardless of treatment. We postulate that this treatment unresponsiveness is due to apoptosis resistance. BCL-XL is an anti-apoptotic member of the BCL-2 protein family, and is over-expressed in mesothelioma. Attenuated expression of other anti-apoptotic proteins and normal pro-apoptotic protein expression is noted in this tumor. Data from our laboratory suggests that constitutive transcriptional activation of the bcl-xl gene is responsible for protein over-expression. We have demonstrated bcl-xl down-regulation in human mesothelioma cells at the protein and mRNA level by both antisense oligonucleotide and full-length adenoviral antisense constructs leads to apoptotic human cell death in vitro. Down-regulation of bcl-xl also sensitizes mesothelioma cells to subsequent in vitro chemotherapy exposure leading to additive or synergistic cellular death. Pilot studies evaluating in vivo down-regulation of bcl-xl utilizing an adenoviral vector antisense construct or antisense oligonucleotides demonstrate inhibition of mesothelioma tumor growth. These experimental results suggest the following hypotheses: (1) bcl-xl expression is abnormal in mesothelioma due to up-regulation of constitutive transcriptional activity, (2) bcl-xl over-expression is in part responsible for mesothelioma clinical treatment resistance, (3) down-regulation of bcl-xl expression will lead to a bcl-2 family protein “imbalance” favoring apoptosis, (4) in vivo administration of bcl-xl antisense oligonucleotides will lead to BCL-XL down-regulation and apoptotic death of mesothelioma tumor cells, and (5) down-regulation of BCL-XL expression in vivo will sensitize mesothelioma tumor cells to conventional treatments such as chemotherapy and ionizing radiation. We will test the hypotheses regarding constitutive transcriptional activation by evaluation of the known transcriptional pathways and promoter function for bcl-xl. In vivo treatment hypotheses will be tested by use of established animal xenograft treatment models of mesothelioma. Our goals are to understand the mechanism of transcriptional up-regulation of the bcl-xl gene in this tumor, and to find a more effective clinical treatment for malignant mesothelioma. A more complete knowledge of bcl-xl constitutive up-regulation mechanisms could be of therapeutic import for a number of solid tumors that have a similar bcl-2 family phenotype. Upstream targets regulating bcl-xl expression for use in future therapeutic paradigms may be identified.

Tags: Bcl2 Gene /protein, Apoptosis, Gene Expression, Genetic Transcription, Mesothelioma Genetic Regulation, Neoplasm /cancer Genetics, Neoplastic Growth, Oligonucleotide Clinical Research, Gel Mobility Shift Assay, Human Tissue, Immunocytochemistry, Laboratory Mouse, Polymerase Chain Reaction, Tissue /cell Culture, Western Blotting

  • Followup Grant: 7R01CA098545-02
  • Followup Grant: 5R01CA098545-03
  • Followup Grant: 5R01CA098545-04

Abstract: Mesothelioma is an asbestos associated tumor arising from mesothelial cells that line the body cavities. Although the etiology of asbestos induced mesothelioma has been well described, very little is known about the molecular alterations that cause these tumors. Our lack of knowledge regarding the molecular events that cause mesothelioma has hampered efforts to identify alternative fibers that can be used as safe asbestos substitutes and has contributed to a diagnostic dilemma in the identification of these tumors. The long range goal of this research is to understand how asbestos fibers transform mesothelial cells. To achieve this goal, the general approach is to identify molecular alterations that occur in transformed mesothelial cells and elucidate the mechanism by which asbestos fibers caused these alterations. The proposed studies are designed to determine the role of the Wilms’ tumor (WT-1) suppressor gene in normal and malignant mesothelial cells. Specific Aims are to 1) Determine the expression pattern of the WT 1 gene in normal and transformed rat mesothelial cells. The expression of the 4 splice variants of WT-1 in normal and transformed mesothelial cells will be examined by PCR to identify differences in gene processing between normal and transformed cells. Using in situ hybridization, WT-1 expression patterns will be correlated with histological subtypes (epithelial, fibrous, mixed) of mesotheliomas to determine if gene expression is regulated by cell differentiation. 2) Identify alterations in the WT-1 gene in transformed rat mesothelial cells. Mutations at the WT-1 gene locus will be identified in cell lines isolated from transformed rat mesothelial cells (spontaneous and asbestos-induced) using direct sequencing of PCR amplified CDNA. To gain information regarding the function of WT-1 in transformed cells, rat mesothelioma cell lines will be transfected with wild type WT-1 to determine the ability of this gene to suppress the transformed phenotype. 3) Establish the similarity or difference in WT-1 alterations between rat and human mesothelioma. Data obtained from the rat cell lines will be expanded to primary rat tumors induced by asbestos and human mesotheliomas to determine if WT-1 is a putative target gene for asbestos. The usefulness of this gene as a biomarker to discriminate between mesothelioma and parenchymal lung tumors will be determined by examining the pattern of expression/alterations in the WT-1 gene in other types of human lung cancer. Information resulting from this research will yield new diagnostic strategies for the identification of mesothelioma and yield mechanistic insights on the role of the WT-1 suppressor gene as a putative gene target for asbestos in mesothelioma development. In addition, these studies will contribute to our knowledge regarding the WT-1 locus by elucidating the function of this gene in an extra-renal neoplasm.

Tags: Wilms’ Tumor, Asbestos, Environment Related Neoplasm /cancer, Mesothelioma, Tumor Suppressor Gene Biomarker, Cell Differentiation, Cell Transformation, Gene Mutation, Genetic Marker, Lung Neoplasm, Molecular Oncology, Neoplasm /cancer Diagnosis, Neoplasm /cancer Genetics, Nucleic Acid Sequence Human Tissue, In Situ Hybridization, Laboratory Mouse, Laboratory Rat, Polymerase Chain Reaction, Tissue /cell Culture

Abstract: Mesothelioma is an asbestos associated tumor arising from mesothelial cells that line the body cavities. Although the etiology of asbestos induced mesothelioma has been well described, very little is known about the molecular alterations that cause these tumors. Our lack of knowledge regarding the molecular events that cause mesothelioma has hampered efforts to identify alternative fibers that can be used as safe asbestos substitutes and has contributed to a diagnostic dilemma in the identification of these tumors. The long range goal of this research is to understand how asbestos fibers transform mesothelial cells. To achieve this goal, the general approach is to identify molecular alterations that occur in transformed mesothelial cells and elucidate the mechanism by which asbestos fibers caused these alterations. The proposed studies are designed to determine the role of the Wilms’ tumor (WT-1) suppressor gene in normal and malignant mesothelial cells. Specific Aims are to 1) Determine the expression pattern of the WT 1 gene in normal and transformed rat mesothelial cells. The expression of the 4 splice variants of WT-1 in normal and transformed mesothelial cells will be examined by PCR to identify differences in gene processing between normal and transformed cells. Using in situ hybridization, WT-1 expression patterns will be correlated with histological subtypes (epithelial, fibrous, mixed) of mesotheliomas to determine if gene expression is regulated by cell differentiation. 2) Identify alterations in the WT-1 gene in transformed rat mesothelial cells. Mutations at the WT-1 gene locus will be identified in cell lines isolated from transformed rat mesothelial cells (spontaneous and asbestos-induced) using direct sequencing of PCR amplified CDNA. To gain information regarding the function of WT-1 in transformed cells, rat mesothelioma cell lines will be transfected with wild type WT-1 to determine the ability of this gene to suppress the transformed phenotype. 3) Establish the similarity or difference in WT-1 alterations between rat and human mesothelioma. Data obtained from the rat cell lines will be expanded to primary rat tumors induced by asbestos and human mesotheliomas to determine if WT-1 is a putative target gene for asbestos. The usefulness of this gene as a biomarker to discriminate between mesothelioma and parenchymal lung tumors will be determined by examining the pattern of expression/alterations in the WT-1 gene in other types of human lung cancer. Information resulting from this research will yield new diagnostic strategies for the identification of mesothelioma and yield mechanistic insights on the role of the WT-1 suppressor gene as a putative gene target for asbestos in mesothelioma development. In addition, these studies will contribute to our knowledge regarding the WT-1 locus by elucidating the function of this gene in an extra-renal neoplasm.

Tags: Wilms’ Tumor, Asbestos, Environment Related Neoplasm /cancer, Mesothelioma, Tumor Suppressor Gene Biomarker, Cell Differentiation, Cell Transformation, Gene Mutation, Genetic Marker, Lung Neoplasm, Molecular Oncology, Neoplasm /cancer Diagnosis, Neoplasm /cancer Genetics, Nucleic Acid Sequence Gene Targeting, Human Tissue, In Situ Hybridization, Laboratory Mouse, Laboratory Rat, Polymerase Chain Reaction, Tissue /cell Culture

  • Followup Grant: 5R01ES006658-04
  • Followup Grant: 5R01ES006658-03

Abstract: DESCRIPTION: (Applicant’s Abstract) One in six people will die of cancer. the systemic nature, recall ability and exquisite specificity of the immune system makes immunotherapy an attractive prospect for cancer treatment. Hepatocellular carcinoma, cervical carcinoma, various leukemias and lymphomas all have proposed viral etiologies. Viral encoded tumor specific antigens make viral associated tumors strong candidates for immunotherapy. Recent studies have described the presence of simian virus 40 (SV40)-like gene sequences and proteins (specifically the large tumor antigen: SV40 Tag) in human osteosarcomas, glioblastomas, ependymomas and malignant pleural mesotheliomas (MPM), demonstrating SV40 association with certain human malignancies. To facilitate the development of human clinical protocols for the immunotherapy of SV40 associated human malignancies, the proposed study will employ an SV40 murine tumor system to evaluate the efficacy of CTL transfer therapies and peptide based vaccines designed to target an immune response to SV40 Tag expressing tumors in vivo. Briefly, SV40 Tag specific CTL will be generated by immunization of Balb/c mice with SV40 Tag gene constructs and the epitope specificity determined by using selected H-2d restricted synthetic peptides representing potential CTL epitopes on SV40 Tag. These CTL will be utilized to examine the ability of adoptively transferred T cells to protect against tumor challenge in syngeneic mice. Further, selected synthetic peptides will be examined for the ability to actively induce protective tumor immunity in vivo. Completion of this study will provide valuable information on the active induction of tumor destructive immunity involving SV40 Tag-epitope specific CTL in vivo. Moreover, the information generated using the murine SV40 tumor model will expedite the development of reagents and clinical trials designed to examine SV40 Tag specific immunotherapies for SV40 associated human malignancies.

Tags: Cytotoxic T Lymphocyte, Neoplasm /cancer Immunology, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Vaccine, Nonhuman Therapy Evaluation, Simian Virus 40, Tumor Antigen Mhc Class I Antigen, Astrocytoma, Disease /disorder Model, Drug Screening /evaluation, Ependymoma, Immunogenetics, Mesothelioma, Neoplastic Cell, Neoplastic Transformation, Osteosarcoma, Synthetic Peptide, Virus Antigen, Virus Genetics, Virus Protein, Virus Related Neoplasm /cancer Active Immunization, Laboratory Mouse

Abstract: The Southwest Oncology Group is a major multidisease, multidisciplinary cooperative therapeutic research organization with 29 Member Institutions, 22 Community Clinical Oncology Programs (CCOPs) and 148 Cooperative Group Outreach Program (CGOP) Centers throughout the country. The scientific thrust of the Group is through multidisciplinary disease oriented committees which develop important, testable hypotheses in the management of each tumor category. The Group is a powerful tool in the design and conduct of innovative therapeutic research. The long-term objective is improved treatment and potential cure of many currently incurable malignancies. This Competative Renewal Application differs from past applications in that the Southwest Oncology Group has developed a series of new initiatives designed to enhance urological cancer research, and melanoma research as well as to extend the scientific thrust of the Group from the basic science standpoint in leukemia, lymphoma and flow cytometry of many tumor categories.

Tags: Blood And Re System, Bone Marrow Transplantation, Neoplasms Of Blood And Re System, Leukemia Acute, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Skin, Melanoma, Neoplasms, Pediatric, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Radiotherapy Adrenal Cortex Hormones Analogs, Dexamethasone, Adrenal Cortex Hormones Analogs, Prednisone, Alkaloids, Vincristine, Antibiotics, Anthracyclines, Daunomycin, Antibiotics, Mithramycin, Antibiotics, Mitomycin C, Antineoplastic Agents, Antineoplastic Agents, Biological Response Modifiers, Aziridines, Bacteria, Actinomycetales, Bacillus Calmette-guerin, Benzo-alpha-pyrones, Cell Sorting, Laser, Children, Congenital Abnormalities, Skin, Nevus, Drugs Adverse Effects, Drugs Resistance, Drugs, Chemotherapy, Drugs Combination, Estratriene Series, Estrogens, Genetics, Cytogenetics, Genetics, Genes, Gene Amplification, Genetics, Genes, Gene Expression, Genetics, Genes, Proto-oncogenes, Genetics, Mutation, Chromosome Mutation, Chromosome Translocations, Guanidines, Cimetidine, Haloalkylamines, Bcnu, Haloalkylamines, Cyclophosphamide, Halopyrimidines, Halouracil, Fluorouracil, Immunity, Cytokines, Lymphokines, Interferons, Immunity, Cytokines, Lymphokines, Interleukin 2, Information Gathering (data Collection), Metals, Heavy Metals, Platinum (compounds), Cis Platinum Compounds, Neoplasms Classification And Staging, Neoplasms Diagnosis, Immunodiagnosis Of Neoplasms, Neoplasms Immunization (immunotherapy), Neoplasms Immunology, Tumor Antigens, Neoplasms Of Blood And Re System, Bone Marrow Neoplasms, Multiple Myeloma, Neoplasms Of Blood And Re System, Leukemia Chronic, Neoplasms Of Blood And Re System, Leukemia Lymphocytic, Neoplasms Of Blood And Re System, Leukemia Myeloid, Neoplasms Of Blood And Re System, Leukemia, Hairy T-cell Leukemia, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Brain, Neoplasms Of Gastrointestinal System, Neoplasms Of Nervous System, Glioma, Astrocytoma, Neoplasms Of Reproductive System Female, Neoplasms Of Reproductive System Female, Ovary Neoplasms, Neoplasms Of Reproductive System Female, Uterus Neoplasms, Neoplasms Of Reproductive System Female, Uterus Neoplasms, Cervix Neoplasms, Neoplasms Of Reproductive System Male, Prostate Neoplasms, Neoplasms Of Reproductive System Male, Testis Neoplasms, Neoplasms Of Skeletal System, Osteogenic Sarcoma, Neoplasms Of Urinary Tract, Kidney Neoplasms, Neoplasms Of Urinary Tract, Urinary Bladder Neoplasms, Neoplasms Surgery, Neoplasms, Sarcoma, Neoplastic Therapy, Combination Antineoplastic Therapy, Nucleic Acids, Mrna, Nursing, Nursing Care, Oncology Nursing, Pyrimidine Nucleosides, Cytosine Nucleosides, Cytosine Arabinoside, Radiation Therapy, Extracorporeal Radiation, Reproductive System Disorders Male, Penile Disorders, Therapy Evaluation, Human, Tissue (cell) Culture, Clone Cells, Tissue Compatibility-transplant, Transplantation Autologous, Cooperative Study Human, Clinical, Nucleic Acids, Nucleic Acid Probes

  • Followup Grant: 5U10CA032102-09
  • Followup Grant: 5U10CA032102-10

Abstract: The Southwest Oncology Group is a major multidisease, multidisciplinary cooperative therapeutic research organization with 29 Member Institutions, 22 Community Clinical Oncology Programs (CCOPs) and 148 Cooperative Group Outreach Program (CGOP) Centers throughout the country. The scientific thrust of the Group is through multidisciplinary disease oriented committees which develop important, testable hypotheses in the management of each tumor category. The Group is a powerful tool in the design and conduct of innovative therapeutic research. The long-term objective is improved treatment and potential cure of many currently incurable malignancies. This Competative Renewal Application differs from past applications in that the Southwest Oncology Group has developed a series of new initiatives designed to enhance urological cancer research, and melanoma research as well as to extend the scientific thrust of the Group from the basic science standpoint in leukemia, lymphoma and flow cytometry of many tumor categories.

Tags: Acute Leukemia, Acute Lymphoblastic Leukemia, Bone Marrow Transplantation, Breast Neoplasm, Head /neck Neoplasm, Lung Neoplasm, Lymphoma, Melanoma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Radiation Therapy, Pediatric Neoplasm /cancer Bacillus Calmette Guerin, Alpha Benzopyrone, Antineoplastic, Astrocytoma, Autologous Transplantation, Aziridine, Biological Response Modifier, Bladder Neoplasm, Brain Neoplasm, Carmustine, Cervix Neoplasm, Child (0-20), Chromosome Translocation, Chronic Leukemia, Cimetidine, Cis Platinum Compound, Clone Cell, Combination Antineoplastic Therapy, Combination Chemotherapy, Cooperative Study, Cyclophosphamide, Cytogenetics, Cytosine Arabinoside, Data Collection, Daunorubicin, Dexamethasone, Drug Adverse Effect, Drug Resistance, Estrogen, Extracorporeal Radiation, Female Reproductive System Neoplasm, Fluorescence Activated Cell Sorter, Fluorouracil, Gastrointestinal Neoplasm, Gene Amplification, Gene Expression, Hairy T Cell Leukemia, Human Therapy Evaluation, Interferon, Interleukin 2, Kidney Neoplasm, Lymphocytic Leukemia, Mesothelioma, Messenger Rna, Mithramycin, Mitomycin C, Multiple Myeloma, Myeloid Leukemia, Neoplasm /cancer Classification /staging, Neoplasm /cancer Immunodiagnosis, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Surgery, Nevus, Oncology Nursing, Osteogenic Sarcoma, Ovary Neoplasm, Penis Disorder, Prednisone, Prostate Neoplasm, Protooncogene, Sarcoma, Testis Neoplasm, Tumor Antigen, Uterus Neoplasm, Vincristine Human Clinical Subject, Nucleic Acid Probe

Abstract: The Southwest Oncology Group is a major multi-disease, multi-disciplinary cooperative group organization, which includes 36 Member Institutions, 25 Community Clinical Oncology Programs (CCOPs), and 265 Cooperative Group Outreach Program affiliates (CGOPs) centered throughout the United States and Canada. New program initiatives have brought on 25 Urologic Cancer Oncology Program (UCOP) affiliates and 34 High Priority participants to add to the Group’s total annual accrual of approximately 7000 patients. this Competitive Renewal Application is submitted to fund the Southwest Oncology Group as a research base for the current and proposed Community Clinical Oncology Program participants. Significant components of this application include a major emphasis of this cooperative group to increase minority participation in clinical trials through the addition of seven Minority- based CCOPs and the formation of a Minorities Subcommittee in the Cancer Control Research Committee. The Southwest Oncology Group also continues to promote and strengthen its internationally-known expertise in cancer control and prevention research through the efforts of the Cancer Control Research Committee, particularly in the areas of quality of life and chemoprevention.

Tags: Cancer Information System, Cancer Prevention, Cancer Rehabilitation /care, Community Health Service, Health Science Research Analysis /evaluation, Human Therapy Evaluation, Neoplasm /cancer Education, Neoplasm /cancer Therapy, Patient Care Planning 13 Cis Retinoate, Cns Neoplasm, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Antineoplastic, Autologous Transplantation, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Breast Neoplasm, Cancer Registry /resource, Carcinogenesis Inhibitor, Carmustine, Cervix Neoplasm, Chronic Leukemia, Cis Platinum Compound, Clinical Study /trial, Colon Neoplasm, Colorectal Neoplasm, Combination Antineoplastic Therapy, Combination Chemotherapy, Continuing Education, Cooperative Study, Cyclophosphamide, Cytosine Arabinoside, Diaziquone, Doxorubicin, Estrogen Receptor, Etoposide, Fluorouracil, Folate, Germ Cell Neoplasm, Glioma, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Ifosfamide, Interferon, Interleukin 2, Isoquinoline, Kidney Neoplasm, Lomustine, Lung Neoplasm, Lymphoma, Male Reproductive System Neoplasm, Mechlorethamine, Melanoma, Mesothelioma, Metastasis, Methotrexate, Multiple Myeloma, Mycosis Fungoides Lymphoma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Hormone Therapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Nutrition Therapy, Neoplasm /cancer Radiation Therapy, Oat Cell Carcinoma, Ovary Neoplasm, Pancreas Neoplasm, Patient /disease Registry, Peptide Hormone Analog, Platinum, Prednisone, Procarbazine, Prostate Neoplasm, Quality Of Life, Reproductive System Neoplasm, Tamoxifen, Testis Neoplasm, Tumor Necrosis Factor Alpha, Uterus Neoplasm, Vincristine Human Clinical Subject

  • Followup Grant: 5U10CA037429-08

Abstract: The Southwest Oncology Group is a major multi-disease, multi-disciplinary cooperative group organization, which includes 36 Member Institutions, 25 Community Clinical Oncology Programs (CCOPs), and 265 Cooperative Group Outreach Program affiliates (CGOPs) centered throughout the United States and Canada. New program initiatives have brought on 25 Urologic Cancer Oncology Program (UCOP) affiliates and 34 High Priority participants to add to the Group’s total annual accrual of approximately 7000 patients. this Competitive Renewal Application is submitted to fund the Southwest Oncology Group as a research base for the current and proposed Community Clinical Oncology Program participants. Significant components of this application include a major emphasis of this cooperative group to increase minority participation in clinical trials through the addition of seven Minority- based CCOPs and the formation of a Minorities Subcommittee in the Cancer Control Research Committee. The Southwest Oncology Group also continues to promote and strengthen its internationally-known expertise in cancer control and prevention research through the efforts of the Cancer Control Research Committee, particularly in the areas of quality of life and chemoprevention.

Tags: Cancer Information System, Cancer Rehabilitation /care, Community Health Service, Health Science Research Analysis /evaluation, Human Therapy Evaluation, Neoplasm /cancer Education, Neoplasm /cancer Therapy, Patient Care Planning 13 Cis Retinoate, Cns Neoplasm, Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Antineoplastic, Autologous Transplantation, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Breast Neoplasm, Cancer Registry /resource, Carcinogenesis Inhibitor, Carmustine, Cervix Neoplasm, Chemoprevention, Chronic Leukemia, Cis Platinum Compound, Clinical Study /trial, Colon Neoplasm, Colorectal Neoplasm, Combination Antineoplastic Therapy, Combination Chemotherapy, Continuing Education, Cooperative Study, Cyclophosphamide, Cytosine Arabinoside, Diaziquone, Doxorubicin, Estrogen Receptor, Etoposide, Fluorouracil, Folate, Germ Cell Neoplasm, Glioma, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Hormone Therapy, Ifosfamide, Interferon, Interleukin 2, Isoquinoline, Kidney Neoplasm, Lomustine, Lung Neoplasm, Lymphoma, Male Reproductive System Neoplasm, Mechlorethamine, Melanoma, Mesothelioma, Metastasis, Methotrexate, Multiple Myeloma, Mycosis Fungoides Lymphoma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Nutrition Therapy, Neoplasm /cancer Radiation Therapy, Ovary Neoplasm, Pancreas Neoplasm, Patient /disease Registry, Peptide Hormone Analog, Platinum, Prednisone, Procarbazine, Prostate Neoplasm, Quality Of Life, Reproductive System Neoplasm, Small Cell Carcinoma Of Lung, Tamoxifen, Testis Neoplasm, Tumor Necrosis Factor Alpha, Uterus Neoplasm, Vincristine Human Subject, Nutrition Related Tag

Abstract: The Southwest Oncology Group is a major multi-disease, multi-disciplinary cooperative group organization, which includes 36 Member Institutions, 25 Community Clinical Oncology Programs (CCOPs), and 265 Cooperative Group Outreach Program affiliates (CGOPs) centered throughout the United States and Canada. New program initiatives have brought on 25 Urologic Cancer Oncology Program (UCOP) affiliates and 34 High Priority participants to add to the Group’s total annual accrual of approximately 7000 patients. this Competitive Renewal Application is submitted to fund the Southwest Oncology Group as a research base for the current and proposed Community Clinical Oncology Program participants. Significant components of this application include a major emphasis of this cooperative group to increase minority participation in clinical trials through the addition of seven Minority- based CCOPs and the formation of a Minorities Subcommittee in the Cancer Control Research Committee. The Southwest Oncology Group also continues to promote and strengthen its internationally-known expertise in cancer control and prevention research through the efforts of the Cancer Control Research Committee, particularly in the areas of quality of life and chemoprevention.

Tags: Cancer Information System, Cancer Rehabilitation /care, Community Health Service, Health Science Research Analysis /evaluation, Human Therapy Evaluation, Neoplasm /cancer Education, Neoplasm /cancer Therapy, Patient Care Planning 13 Cis Retinoate, Cns Neoplasm, Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Antineoplastic, Autologous Transplantation, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Breast Neoplasm, Cancer Registry /resource, Carcinogenesis Inhibitor, Carmustine, Cervix Neoplasm, Chemoprevention, Chronic Leukemia, Cis Platinum Compound, Clinical Trial, Colon Neoplasm, Colorectal Neoplasm, Combination Antineoplastic Therapy, Combination Chemotherapy, Continuing Education, Cooperative Study, Cyclophosphamide, Cytosine Arabinoside, Diaziquone, Doxorubicin, Estrogen Receptor, Etoposide, Fluorouracil, Folate, Germ Cell Neoplasm, Glioma, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Hormone Therapy, Ifosfamide, Interferon, Interleukin 2, Isoquinoline, Kidney Neoplasm, Lomustine, Lung Neoplasm, Lymphoma, Male Reproductive System Neoplasm, Mechlorethamine, Melanoma, Mesothelioma, Metastasis, Methotrexate, Multiple Myeloma, Mycosis Fungoides Lymphoma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Nutrition Therapy, Neoplasm /cancer Radiation Therapy, Ovary Neoplasm, Pancreas Neoplasm, Patient /disease Registry, Peptide Hormone Analog, Platinum, Prednisone, Procarbazine, Prostate Neoplasm, Quality Of Life, Reproductive System Neoplasm, Small Cell Carcinoma Of Lung, Tamoxifen, Testis Neoplasm, Tumor Necrosis Factor Alpha, Uterus Neoplasm, Vincristine Human Subject, Nutrition Related Tag

Abstract: Disordered fibrin turnover has been implicated in the pathogenesis of pleural inflammation and repair. We hypothesize that deranged regulation of plasminogen activator inhibitor-1 (PAI-1) and of the urokinase receptor (uPAR) in pleural mesothelial cells are critical determinants of locally impaired fibrinolysis and intrapleural remodeling after asbestos exposure or in fibrosing pleuritis. Mechanisms that regulate expression of these proteins in mesothelial cells are now poorly understood. We will extend work done in previous funding cycles to address these important gaps. We will achieve this objective in four closely integrated specific aims. In Aim 1, we will determine mechanisms that regulate the expression of PAI-1 and uPAR in mesothelial cells exposed to asbestos or mediators of fibrosing pleural injury. In Aims 2 and 3, we will elucidate mechanism(s) by which PAI-1 is regulated by pleural mesothelial cells at the posttranscriptional level and will determine how control at this level influences pathophysiologic responses of these cells. In Aim 4, we will further test a novel interventional approach; intrapleural administration of single-chain uPA (scuPA) to prevent pleural loculation. We will use our established rabbit models of tetracycline- or P. multocida induced pleural injury in these studies. To accomplish the work, we will use a wide range of molecular, biochemical and histologic techniques, all of which are well-established in our laboratory. These studies will foster better understanding of the role of the mesothelial cell in the regulation of the PAI-1-uPA-uPAR system and will increase our understanding of how these cells contribute to pleural remodeling after injury. The project will also facilitate the development of novel, clinically applicable non-surgical approaches to prevent intrapleural loculation and its associated morbidity.

Tags: Fibrin, Fibrinolysis, Lung Disorder, Pathologic Process, Plasminogen Activator Inhibitor, Pleural Cavity Effusion Rna Binding Protein, Mesothelioma, Posttranscriptional Rna Processing, Protein Binding, Protein Biosynthesis, Protein Protein Interaction, Receptor Expression, Urokinase Cell Line, Human Tissue, Immunocytochemistry

  • Followup Grant: 5P01HL076406-020001
  • Followup Grant: 5P01HL076406-030001
  • Followup Grant: 5P01HL076406-040001

Abstract: DESCRIPTION: (Applicant’s Abstract) Although asbestos exposure causes human disease such as asbestosis, lung carcinoma, and mesothelioma, the mechanism of toxicity is not clearly understood. Abundant evidence suggests that free radicals mediate its toxicity, the target of which, however, is not clearly defined. The goal of this proposal is to further clarify the cellular and molecular mechanisms of asbestos toxicity and define a basis for the prevention of asbestos-related diseases. This will be attained by an in vitro model system using a unique DNA repair deficient mutant cell line. Two hypotheses to be tested are 1) DNA double strand breaks (DSBs) produced by free radicals play a critical role in asbestos induced toxicity; if DNA DSBs are not repaired or misrepaired, cells are killed. 2) Reduction in initial DNA damage by an antioxidant agent in asbestos treated cells results in reduction of cytotoxicity. The following specific aims are proposed to test these hypotheses. i) To investigate the effect of DNA DSB and repair on cell survival using a DNA DSB repair deficient mutant of CHO cells (xrs-5 cells) treated with asbestos fibers. Colony formation assay will be employed in xrs-5 and CHO cells exposed to asbestos. ii) To directly measure the degree of DNA DSBs in asbestos treated CHO and xrs-5 cells by a pulsed-field gel electrophoresis. The premature chromosome condensation technique which can detect interphase chromosome breaks will be applied to further clarify the sequence of events from DNA damage to cell death. iii) To examine the effect of an anti-oxidant in asbestos induced cell killing and DNA DSBs using CHO cells. The cell survival assay will be employed but with combined treatments of asbestos and ascorbic acid. DNA DSBs will be examined with samples of the combined treatments as in ii). All of these studies will be conducted with chrysotile and crocidolite fibers (with higher iron content) to examine the catalytic power of iron in crocidolites. The results from these studies shall clarify the role of DNA damage/repair, specifically DNA DSBs, in asbestos induced toxicity, and may provide a useful basis for reducing the toxicity.

Tags: Dna Damage, Dna Repair, Asbestos, Cytotoxicity, Environmental Toxicology Antioxidant, Ascorbate, Free Radical Oxygen, Iron, Oxidative Stress Cho Cell, Mutant, Pulsed Field Gel Electrophoresis, Tissue /cell Culture

Abstract: There is no text on file for this abstract.

Tags: Dna Damage, Dna Repair, Asbestos, Chemical Carcinogenesis, Free Radical Oxygen Adduct, Antioxidant, Chemical Carcinogen, Fibroblast, Hypoxanthine Phosphoribosyltransferase, Mesothelioma, Mitochondrial Dna, Neoplasm /cancer Genetics, Nucleic Acid Sequence, Tumor Suppressor Gene, Xeroderma Pigmentosum Gas Chromatography Mass Spectrometry, High Performance Liquid Chromatography, Polymerase Chain Reaction

  • Followup Grant: 5R01ES007038-02
  • Followup Grant: 5R01ES007038-04
  • Followup Grant: 5R01ES007038-05

Clinical Trials

Condition: Mesothelioma
Intervention: Drug: bevacizumab; Drug: cisplatin; Drug: pemetrexed
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Condition: Mesothelioma; Lung Cancer
Intervention: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683); Drug: Comparator: Placebo
More Information

Condition: Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Sarcoma
Intervention: Drug: L-alanosine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

Condition: Malignant Mesothelioma
Intervention: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: liposomal NDDP; Procedure: thoracoscopic surgery
More Information

Condition: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Malignant Mesothelioma; Pancreatic Cancer; Small Intestine Cancer
Intervention: Biological: recombinant interleukin-12
More Information

Condition: Mesothelioma
Intervention: Drug: Cisplatin; Drug: Imatinib Mesylate; Drug: Pemetrexed
More Information

Condition: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Intervention: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: antineoplaston A10; Drug: antineoplaston AS2-1
More Information

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Dasatinib
More Information

Condition: Carcinoma, Non-Small-Cell Lung; Mesothelioma
Intervention: Drug: LBH589
More Information

Condition:
Intervention:
More Information

Condition: Pleural Neoplasms
Intervention: Drug: pemetrexed; Drug: cisplatin
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Condition: Cancer
Intervention: Drug: fentanyl sublingual spray; Other: questionnaire administration
More Information

Condition: Metastatic Non-squamous Non Small Cell Lung Cancer
Intervention: Drug: CBP501 + Cisplatin + Pemetrexed; Drug: Cisplatin + Pemetrexed
More Information

Hospitals and Cancer Centers

University of Texas-MD Anderson Cancer Center
1515 Holcombe Blvd Unit 432
Houston, TX
713.792.6363

Physicians

Department Of Clinical Investigation
University of Texas, MD Anderson Cancer Center
1515 Holcombe Blvd., P.O. Box 39
Houston, TX 77030
(713) 792-7959

Paul Mansfield, M.D.
M.D. Anderson Cancer Center
1515 Holcombe Blvd Ste 444
Houston, TX 77030
(713) 792-6161

In re E.I. du Pont de Nemours & Co.
NO. 08-0625, SUPREME COURT OF TEXAS, July 3, 2009, Opinion Delivered

In re GE Co.
NO. 07-0195, SUPREME COURT OF TEXAS, November 14, 2007, Argued, December 5, 2008, Opinion Delivered

In re Global Sante Fe Corp.
No. 07-0040, SUPREME COURT OF TEXAS, January 16, 2008, Argued, December 5, 2008, Opinion Delivered

Borg-Warner Corp. v. Flores
NO. 05-0189, SUPREME COURT OF TEXAS, September 29, 2006, Argued , June 8, 2007, Opinion Delivered

Hallco Tex., Inc. v. McMullen County
NO. 02-1176 , SUPREME COURT OF TEXAS, January 4, 2005, Argued , December 29, 2006, Opinion Delivered

In re Van Waters & Rogers, Inc.
NO. 03-0777 , SUPREME COURT OF TEXAS, September 3, 2004, Delivered

Pustejovsky v. Rapid-American Corp.
NO. 98-1128, SUPREME COURT OF TEXAS, September 8, 1999, Argued , November 30, 2000, Opinion Issued

Todd Shipyards Corp. v. Perez
NO. 99-0697, SUPREME COURT OF TEXAS, May 18, 2000, Delivered

Temple-Inland Prods. Corp. v. Carter
No. 97-0592, SUPREME COURT OF TEXAS, October 21, 1998, Argued , April 29, 1999, Delivered

Union Carbide Corp. v. Smith
NO. 01-08-00641-CV, COURT OF APPEALS OF TEXAS, FIRST DISTRICT, HOUSTON, October 1, 2009, Opinion Issued

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.

Get your free copy of
“Surviving Mesothelioma” Today!